These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

282 related items for PubMed ID: 17036279

  • 1. [Cardioverter-defibrillator (ICD) and resynchronization in every patient with cardiac failure].
    Mundhenke M.
    Dtsch Med Wochenschr; 2006 Oct 13; 131(41):2297-8; author reply 2298. PubMed ID: 17036279
    [No Abstract] [Full Text] [Related]

  • 2. [Therapy of heart failure after myocardial infarction. With eplerenone a new course].
    MMW Fortschr Med; 2004 Oct 21; 146(43):58-9. PubMed ID: 15559524
    [No Abstract] [Full Text] [Related]

  • 3. Neurohormonal Antagonists Are Preferred to an Implantable Cardioverter-Defibrillator in Preventing Sudden Death in Heart Failure.
    Packer M.
    JACC Heart Fail; 2019 Oct 21; 7(10):902-906. PubMed ID: 31521684
    [No Abstract] [Full Text] [Related]

  • 4. Treatment of heart failure with ACE inhibitors and beta-blockers: what is next? Aldosterone receptor antagonists?
    van der Horst IC, Voors AA, van Veldhuisen DJ.
    Clin Res Cardiol; 2007 Apr 21; 96(4):193-5. PubMed ID: 17294352
    [No Abstract] [Full Text] [Related]

  • 5. ICDs Are Still an Effective Therapy to Prevent Sudden Cardiac Death in Heart Failure.
    DeVore AD, Al-Khatib SM.
    JACC Heart Fail; 2019 Oct 21; 7(10):907-910. PubMed ID: 31521688
    [No Abstract] [Full Text] [Related]

  • 6. Waiting Period Before Implantable Cardioverter-Defibrillator Implantation in Newly Diagnosed Heart Failure With Reduced Ejection Fraction: A Window of Opportunity.
    DeFilippis EM, Butler J, Vaduganathan M.
    Circ Heart Fail; 2017 Nov 21; 10(11):. PubMed ID: 29138249
    [No Abstract] [Full Text] [Related]

  • 7. [Aldosterone antagonists for all patients with heart failure?].
    Bauersachs J.
    MMW Fortschr Med; 2009 Apr 09; 151(15):33-5. PubMed ID: 19728679
    [No Abstract] [Full Text] [Related]

  • 8. Efficacy of Pharmacologic and Cardiac Implantable Electronic Device Therapies in Patients With Heart Failure and Reduced Ejection Fraction: A Systematic Review and Network Meta-Analysis.
    Tseng AS, Kunze KL, Lee JZ, Amin M, Neville MR, Almader-Douglas D, Killu AM, Madhavan M, Cha YM, Asirvatham SJ, Friedman PA, Gersh BJ, Mulpuru SK.
    Circ Arrhythm Electrophysiol; 2019 Jun 09; 12(6):e006951. PubMed ID: 31159582
    [Abstract] [Full Text] [Related]

  • 9. Prevention of sudden death in heart failure with reduced ejection fraction: do we still need an implantable cardioverter-defibrillator for primary prevention?
    Abdelhamid M, Rosano G, Metra M, Adamopoulos S, Böhm M, Chioncel O, Filippatos G, Jankowska EA, Lopatin Y, Lund L, Milicic D, Moura B, Ben Gal T, Ristic A, Rakisheva A, Savarese G, Mullens W, Piepoli M, Bayes-Genis A, Thum T, Anker SD, Seferovic P, Coats AJS.
    Eur J Heart Fail; 2022 Sep 09; 24(9):1460-1466. PubMed ID: 35753058
    [Abstract] [Full Text] [Related]

  • 10. Lessons Learned and Insights Gained in the Design, Analysis, and Outcomes of the COMPANION Trial.
    Bristow MR, Saxon LA, Feldman AM, Mei C, Anderson SA, DeMets DL.
    JACC Heart Fail; 2016 Jul 09; 4(7):521-535. PubMed ID: 27289408
    [Abstract] [Full Text] [Related]

  • 11. Compelling First-Line Drug and Device Therapies for the Prevention of Sudden Death in Patients With Chronic Heart Failure and a Reduced Ejection Fraction Who Are Candidates for an Implantable Cardioverter-Defibrillator.
    Packer M.
    Circ Arrhythm Electrophysiol; 2019 Jun 09; 12(6):e007430. PubMed ID: 31159583
    [No Abstract] [Full Text] [Related]

  • 12. Rationale, design, and baseline characteristics of the DANish randomized, controlled, multicenter study to assess the efficacy of Implantable cardioverter defibrillators in patients with non-ischemic Systolic Heart failure on mortality (DANISH).
    Thune JJ, Pehrson S, Nielsen JC, Haarbo J, Videbæk L, Korup E, Jensen G, Hildebrandt P, Steffensen FH, Bruun NE, Eiskjær H, Brandes A, Thøgersen AM, Egstrup K, Hastrup-Svendsen J, Høfsten DE, Torp-Pedersen C, Køber L.
    Am Heart J; 2016 Sep 09; 179():136-41. PubMed ID: 27595688
    [Abstract] [Full Text] [Related]

  • 13. Timing of defibrillator implant after acute myocardial infarction: what's new?
    Santini M, Pignalberi C.
    Europace; 2011 Apr 09; 13(4):455-7. PubMed ID: 21186232
    [No Abstract] [Full Text] [Related]

  • 14. [Selective aldosterone blocking in heart failure. Eplerenone reduces the risk after infarction].
    MMW Fortschr Med; 2003 Oct 30; 145(44):42-3. PubMed ID: 14655506
    [No Abstract] [Full Text] [Related]

  • 15. Implantable cardioverter-defibrillator therapy after myocardial infarction.
    Micheletta F, Natoli S, Iuliano L.
    N Engl J Med; 2005 Mar 10; 352(10):1039-41; author reply 1039-41. PubMed ID: 15761993
    [No Abstract] [Full Text] [Related]

  • 16. Aldosterone antagonism in heart failure.
    Richards AM, Nicholls MG.
    Lancet; 1999 Sep 04; 354(9181):789-90. PubMed ID: 10485716
    [No Abstract] [Full Text] [Related]

  • 17. Mortality Effect of ICD in Primary Prevention of Nonischemic Cardiomyopathy: A Meta-Analysis of Randomized Controlled Trials.
    Luni FK, Singh H, Khan AR, Malik SA, Khawaja O, Riaz H, Lee W, Kabour A, Richards M, Aasbo J.
    J Cardiovasc Electrophysiol; 2017 May 04; 28(5):538-543. PubMed ID: 28370885
    [Abstract] [Full Text] [Related]

  • 18. Efficacy of medical therapy for the reduction of heart failure events in patients with implanted cardioverter defibrillators.
    Pietrasik G, Goldenberg I, McNitt S, Polonsky B, Moss AJ, Zareba W.
    J Cardiovasc Electrophysiol; 2009 Apr 04; 20(4):395-400. PubMed ID: 19017351
    [Abstract] [Full Text] [Related]

  • 19. Implantable cardioverter-defibrillators.
    Kukin ML.
    N Engl J Med; 2009 Feb 26; 360(9):937; author reply 937-8. PubMed ID: 19246371
    [No Abstract] [Full Text] [Related]

  • 20.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 15.